CW
ALNY icon

Connectus Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Connectus Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,200
Closed -$1.05M – 421
2022
Q1 		$1.05M Hold
6,200
– – 0.03% 238
2021
Q4 		$1.05M Buy
+6,200
New +$1.15M 0.04% 214

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Connectus Wealth's ALNY Position: Q2 2022 in Review

Connectus Wealth sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2022, closing a stake of 6,200 shares — an estimated $1.05M sold.

Connectus Wealth first reported a position in ALNY in Q4 2021 and held it in 2 quarters. The position peaked at $1.05M in Q1 2022. 423 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

  • Connectus Wealth reported no remaining Alnylam Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Connectus Wealth sold 6,200 Alnylam Pharmaceuticals shares in Q2 2022, an estimated $1.05M.
  • Connectus Wealth first reported a position in Alnylam Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Connectus Wealth's Alnylam Pharmaceuticals position peaked at $1.05M in Q1 2022.
  • 423 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on Connectus Wealth's 13F filing for Q2 2022, filed 8 Aug 2022.